| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 0.63 | 53.7% | 34.0% |
| Total Income | 0.63 | 53.7% | 34.0% |
| Expenditure | 5.73 | 14.5% | 9.6% |
| PBT | — | ||
| Net Profit | -5.38 | 14.3% | 8.3% |
| OPM | — | ||
| NPM | — | ||
| EPS | — |
VolitionRx Announces Q3 2025 Financial Results; Revenue Up 32%
04 May 2026 · 4 May, 7:17 am
Summary
VolitionRx Limited announced its third quarter 2025 financial results, reporting revenue of $0.6 million, a 32% increase compared to the same quarter last year. Operating expenses decreased by 10% year-over-year, and net loss decreased by 8%. The company signed agreements with Werfen and Hologic. Subsequent to the quarter's end, VolitionRx received approximately $6.1 million from a public offering.
Key Highlights
- 1
VolitionRx Limited's revenue for the third quarter was $0.6 million, representing growth of 32% over the same quarter last year.
- 2
Operating expenses for the quarter decreased by 10% year-over-year.
- 3
Net loss for the quarter decreased by 8% compared to the prior year.
- 4
Net cash used in operating activities was $3.6 million for the quarter, down 33% over the same period prior year.
- 5
Subsequent to quarter end, VolitionRx received net proceeds of approximately $6.1 million from a confidentially-marketed public offering, including partial exercise of the underwriter’s overallotment option.
- 6
VolitionRx signed a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome with Werfen.
- 7
VolitionRx signed a Co-Marketing and Services Agreement with Hologic.
Management Comments
Cameron Reynolds
2025 efforts for Volition focused on commercializing our groundbreaking Nu.Q® platform in the human diagnostics market and we were excited this quarter to sign not one, but two human agreements: a Research License and Exclusive Commercial Option Rights Agreement for Antiphospholipid Syndrome ("APS") with Werfen and a Co-Marketing and Services Agreement with Hologic. Both are multi-billion dollar companies, and worldwide leaders in their specialized fields, and we are delighted to report that both have very much hit the ground running. We are in discussions with around 10 of the world’s leading diagnostic and liquid biopsy companies and are at various stages of the process across our different pillars, ranging from due diligence to tech transfer, to evaluation of clinical samples, to term sheet and contract negotiation. We anticipate further human licensing deals with a range of large companies and will update on progress as they are completed. We believe that our positive emerging clinical evidence supports the broad applicability of our Nu.Q® technology in critical areas such as cancer and sepsis, including as a biomarker of interest to epigenetic drug development, an ever expanding area of focus for big pharma. Our goal is to secure a range of licensing agreements in the human diagnostics space, mirroring our successful strategy in the veterinary market, and anticipate, similar to the veterinary market, diverse deal structures, with potential for up front and milestone payments, and future recurring revenue. We believe we have developed a unique and widely applicable platform that will contribute significantly to oncology and NETosis detection and monitoring for decades to come, and for hundreds of millions of people and animals worldwide.”
Informational and educational content only. Not investment advice.